Anivive Lifesciences, Inc.

The company plans to conduct a Phase I clinical trial of the vaccine in humans. Credit: Billion Photos / Shutterstock. Anivive Lifesciences, a One Health technology company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID) to support the development of a human vaccine against coccidioides, the fungus responsible for valley fever. The $33m contract will leverage the science behind Anivive’s canine valley fever vaccine, which is under review by the United States Department of Agriculture’s Center for Veterinary Biologics. This approach will help to develop a similar vaccine for use in humans. The NIAID funding will facilitate investigational new drug (IND)-enabling activities such as manufacturing enhancements, formulation, comprehensive safety assessments and an IND submission. A Phase I clinical trial in humans will then be conducted. See Also: FDA approves J&J’s multiple myeloma therapy Pharmaceutical Technology Excellence Awards 2024: SecureCHEK AI The initiative comes at a time when climate change is increasing the prevalence of fungal diseases, prompting the World Health Organization to call for intensified research and policy improvements in 2022. No antifungal vaccines have yet received approval for use in either humans or animals. Anivive Lifesciences chief strategy officer and principal investigator Dr Edward Robb said: “Anivive is honoured to receive this NIAID contract, which will greatly accelerate our efforts to commercialise a vaccine to protect people against valley fever. “This collaborative effort has delivered a significant step forward in the field of vaccinology and holds the potential to be the first vaccine to prevent a serious systemic fungal infection common to humans and animals.” The company’s efforts are bolstered by collaborations with the Valley Fever Center for Excellence at the University of Arizona College of Medicine, Recipharm , Quigley BioPharma and the Latham BioPharm Group, part of Sia Partners. The collaborators provide a range of support services from non-clinical development to programme management. Anivive, headquartered in the US, operates at the nexus of biotechnology, artificial intelligence and software. Its pipeline features eight first-in-class technologies targeting oncology, virology and infectious diseases.

LONG BEACH, Calif., Aug. 2, 2024 /PRNewswire/ -- Anivive Lifesciences Inc, a One Health technology company today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded Anivive a new contract (#75N93024C00009) worth up to $33M to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever. Continue Reading Contract funding aims to utilize the underlying science in Anivive's animal health Valley Fever vaccine for dogs, currently under review by USDA Center for Veterinary Biologics, to develop a similar vaccine for humans. The funding will address IND-enabling activities, including additional manufacturing, formulation, extensive safety testing, and an IND submission, before then completing a human Phase 1 clinical trial. ... holds potential to be the first vaccine to prevent a serious systemic fungal infection common to humans and animals. Post this Rising temperatures and extreme weather are setting the stage for increases in fungal diseases. Recognizing the growing global public health problem, in 2022, the World Health Organization (WHO) released its first-ever list of fungal "priority pathogens," calling for policy improvements and research in such areas as fungal disease distribution, patterns of antifungal resistance, and who is most at risk of exposure and disease. Currently, there are no antifungal vaccines approved for human or animal use. "Anivive is honored to receive this NIAID contract, which will greatly accelerate our efforts to commercialize a vaccine to protect people against Valley Fever," said Dr. Edward Robb, Anivive Lifesciences Chief Strategy Officer and Principal Investigator. "This collaborative effort has delivered a significant step forward in the field of vaccinology and holds the potential to be the first vaccine to prevent a serious systemic fungal infection common to humans and animals," said Robb. Anivive has built a strong research team to catalyze this breakthrough and deliver a first-in-class solution for an emerging fungal disease. Additionally, this program is supported by: Valley Fever Center for Excellence at the University of Arizona College of Medicine for the non-clinical development, Recipharm for the contract manufacturing, Quigley BioPharma for vaccine development support and Latham BioPharm Group, part of Sia Partners for the program management, financial compliance, quality assurance and additional technical subject matter expertise. About Anivive Lifesciences Anivive is a pet pharmaceutical company at the intersection of biotech, AI, software, and veterinary medicine. Our proprietary software platform accelerates the development of new, affordable diagnostics, treatments and preventatives for various life-threatening diseases in pets. Anivive's pipeline includes 8+ first-in-class technologies for three critical areas: Oncology, virology and infectious disease. Anivive is a privately held company based in Long Beach, California. Visit  to learn more. About Recipharm Recipharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry employing over 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals and biologics in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden About Quigley BioPharma LLC Quigley BioPharma LLC (Quigley) is a Contract Product Development Organization specializing in strategies to streamline and accelerate advanced development of biological products for prevention and treatment of infectious diseases, cancer and allergies. Quigleys unique, industry-experienced, multi-disciplinary development team with 10 successful product launches offers a turnkey solution to public and private biotechnology and pharmaceutical enterprises allowing flexibility in resource allocation and enhanced return on investment. About Latham BioPharm Group Latham BioPharm Group (LBG) is a leading life science consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies alike to solve complex business, regulatory, and product development challenges. About University of Arizona Valley Fever Center for Excellence The Arizona Board of Regents established the UA Valley Fever Center for Excellence in 1996 for the benefit of the entire state. Based at the UA Health Sciences campus—which includes the UA College of Medicine – Tucson, College of Pharmacy, College of Nursing and Mel and Enid Zuckerman College of Public Health—the center has developed a research base that includes the state's three universities, and an information program for the scientific community and the general public. Its work encompasses public awareness, clinical guidelines and training, and research into rapid detection methods for the disease as well as development of a vaccine for both animals and humans. SOURCE Anivive Lifesciences Inc.

WASHINGTON, April 4, 2024 /PRNewswire/ -- Anivive Lifesciences, is set to unveil groundbreaking research at the upcoming World Vaccine Congress, where they will present findings on the development of the world's first systemic antifungal vaccine – A solution for both ends of the leash. The conference, taking place April 1-4, brings together leading experts and researchers from top scientists and life science companies around the globe to discuss advancements in vaccine development. Continue Reading Anivive to Present Groundbreaking Research on First Systemic Antifungal Vaccine at World Vaccine Congress Post this World Vaccine Congress Dr. Edward Robb, Chief Strategy Officer at Anivive will present for the team and focus on the critical need for effective antifungal vaccines, particularly in light of rising fungal infections worldwide and the challenges associated with developing a fungal vaccine. This collaborative effort, crossing public and private enterprises has delivered a significant breakthrough in the field of vaccinology and holds the potential to be a first to prevent a systemic fungal infection common to both dog and man. Fungal infections pose a serious threat to public health, especially among immunocompromised individuals and those with underlying health conditions. Traditional treatment options often involve lengthy and costly therapies, with the risk of relapse and drug resistance. An antifungal vaccine offers a promising alternative by harnessing the body's immune system to prevent infection altogether. Dr. Robb, whose extensive experience in vaccinology spans decades, leads a dedicated team of researchers at Anivive and collaboration with the Valley Fever Center for Excellence at the University of Arizona. Their collaborative efforts have culminated in the development of a novel vaccine candidate that targets coccidioidomycosis fungal infections. A more common name Is Valley Fever. The presentation by Dr. Robb will provide insights into the vaccine's mechanism of action, preclinical studies demonstrating efficacy, and microbial safety for this first systemic antifungal vaccine. Attendees can expect to gain valuable knowledge about the challenges and opportunities in antifungal vaccine development, as well as the future direction of this pioneering research. "We are at a pivotal moment in the fight against fungal infections," says Dr. Robb. "The development of an antifungal vaccine represents a transformative approach to combating these pervasive and often overlooked pathogens. I am honored to share our findings at the World Vaccine Congress and contribute to the global dialogue on vaccine innovation." The World Vaccine Congress serves as a premier platform for sharing cutting-edge research and fostering collaboration among experts in the field of vaccinology. Dr. Robb's presentation addresses how supporting One Health can meet unmet medical needs by aligning animal, human and environmental health, and how this novel antifungal Valley Fever vaccine supports health on both ends of the leash. For more information about Dr. Robb's presentation and the World Vaccine Congress, please visit Anivive.com About Anivive Lifesciences Anivive is a pet pharmaceutical company at the intersection of biotech, AI, software, and veterinary medicine. Our proprietary software platform accelerates the development of new, affordable treatments for life-threatening diseases in pets. Anivive's pipeline includes 8+ first-in-class therapeutics for three critical areas: Oncology, Anti-Virals and Anti-Fungal Vaccines. To learn more visit SOURCE Anivive Lifesciences Inc.